Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
Saul E. Rivkin
Research Funding - AstraZeneca
Desiree Iriarte
Research Funding - AstraZeneca
Heather Sloan
No relevant relationships to disclose
Cara Wiseman
Research Funding - AstraZeneca
James Moon
No relevant relationships to disclose